Université Libre De Bruxelles

Ucb S.a.

Previsan Ag

Michel Goldman

Patrick Stordeur

Marius Tuijnder

Pierre P Chatelain

H&eacute;l&egrave;ne Margery

Michel Vandevelde

Mathieu Vokaer

Annick Ocmant

Emmanuel Bartholomé

Christel Buelens

Fabienne Willems

Patrick Adelin Oscar Robberecht

Jean Pierre Robert Tassignon

Anne Mignot

Mark Taubman

A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably MxA, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.

Method for evaluating the response of an individual to a treatment with a type I interferon (IFN)

A device and kit for pulsing a biological sample with a pulsing agent is disclosed. The biological sample so pulsed is subsequently stabilized and the device or kit provides a control reaction. Applications for the described device and kit are found in the field of medical diagnostics, particularly immunology.

Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed

The present invention is related to a device, kit and method for pulsing a biological sample with a pulsing agent and subsequently stabilizing the biological sample so pulsed. The invention has application in the fields of medical diagnostics, particularly relating to immunity.

The present invention relates to an in vitro method for differentiation and maturation of isolated monocytes into IL3-R+CD11c+ myeloid dendritic cells consisting of incubating the monocytes with a combination of a type I interferon and IL-3.

Generation and use of dendritic cells

The invention concerns a method for inhibiting cytokine production by cells, in particular animal or human cells, and their secretion, which consists in applying on said cells at least an azo compound derivatives corresponding to formula (I), in which A represents a carboxyl or a group (a); B represents a carboxyl or a group (b); R , R , R and R &equals;H, Hal, OH or a hydrocarbon radical, R and R as well as R and R capable of being a heterocyclic ring; X and X &equals;O or NR , where R &equals;H, Hal, a hydrocarbon radical or a nitro group.

Method for inhibiting cytokine production by cells

A CD40 signal blocking agent comprising, as an active ingredient, s-triazolo&lsqb;1,5-a&rsqb;pyrimidine derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof, is disclosed

Growing community of inventors

Brussels, Belgium

Michel Goldman